Real World Data on Adjuvant Chemotherapy in Stage II Colorectal Cancer: Risk Factors and Benefits

Jaime González-Montero1,2*, Guillermo Valenzuela3, Luis Villanueva1, Mónica Ahumada1,2 and Olga Barajas1,2

1Oncology Section, Internal Medicine Department, University of Chile Clinical Hospital, Chile
2Department of Basic and Clinical Oncology, University of Chile, Chile
3Medicine Student, University of Chile, Chile

*Corresponding author: Jaime González-Montero MD PhD, Department of Basic and Clinical Oncology, University of Chile, 1027 Independencia Avenue, Independencia, Santiago Tel: +56999367446, Chile, Email: jagonzalez@ug.uchile.cl

To Cite This Article: Jaime González Montero, Real World Data on Adjuvant Chemotherapy in Stage II Colorectal Cancer: Risk Factors and Benefits. 2020 - 8(3). AJBSR.MS.ID.001265. DOI: 10.34297/AJBSR.2020.08.001265

Received: March 16, 2020; Published: March 20, 2020

Abstract

Adjuvant chemotherapy (ACh) benefits in stage II colorectal cancer (CRC) is still unclear. Risk factors (RF) as perineural (PNI) or lymphovascular (LVI) infiltrate in biopsy, T4 or less than 12 lymph nodes (LN) resected during surgery has associated with recurrence. We retrospectively evaluated ACh benefits in stage II CRC patients. This retrospective analysis collected information of CRC patients who were treated at University of Chile Clinical Hospital between 2011-2018 and had histological diagnosis of T3-4N0 colon adenocarcinoma. Clinical, surgical, histological variables, and RF were recorded. Disease-free survival (DFS) was compared in patients who underwent ACh with patients who were observed. Of 91 patients, 51% received ACh and 49% observation. DFS was 45 and 36 months in ACh and observation groups (p=0.277). RF were present in 62%, and of these 73% received ACh and 27% observation. There were no association of T4 stage, PNI and/or LVI with improve DFS and response to ACh. Recurrence was presented in 12.6% of patients and 75% of this presented one or more RF. In this retrospective cohort, ACh did not improve DFS compared to observation only. In our study, 25% of recurrences are in patients without RF, therefore it is necessary to improve strategies to predict recurrences and response to ACh. Further studies should evaluate other elements to optimize the decision to administer ACh in these patients, such as microsatellite instability and circulating DNA.

Keywords: Stage II colon cancer, Adjuvant chemotherapy, Perineural, Lymphovascular infiltrate

Abbreviations: CRC: Colorectal Cancer, DFS: Disease-Free Survival, OS: Overall survival, ACh: Adjuvant chemotherapy, RF: Risk Factors, PNI: Perineural Infiltrate, LVI: Lymphovascular Infiltrate, LN: Lymph Nodes, MSI: Microsatellite Instability, FOLFOX: Leucovorin, Fluorouracil and Oxaliplatin, CAPOX: Capecitabine and Oxaliplatin, FU/LV: Fluorouracil and Leucovorin, SD: Standard Deviation

Introduction

Colorectal cancer (CRC) have a growing incidence in developed countries [1,2], and is one of the main causes of mortality due to cancer worldwide [3]. Major improvements in disease-free survival (DFS) and overall survival (OS) in patients with non-metastatic colon cancer has been as a result of improvement of surgery quality [4-6] and continuous clinical trials investigation on adjuvant chemotherapy (ACh) [7-9].

Despite well-established role of ACh as standard treatment in patients with stage III, the current evidence does not support routine ACh in stage II patients [10]. It’s have been shown a 70-80% of curative rates with only surgery in patients with stage II [11], in consequence, selection of patients who are candidate to ACh need to be rigorous. Due to benefit in stage II CRC is still unclear, it must be considered potential toxicity of chemotherapy agents, for instance, the potentially debilitating neuropathy related to oxaliplatin...
as well as the arguably benefit of oxaliplatin in patients >70 years of age [12,13].

It’s have been identified risk factors (RF) based on pathologic and clinical characteristics, according to National Comprehensive Cancer Network (NCCN) guidelines, present of perineural (PNI) or lymphovascular (LVI) infiltrate in biopsy, T4 or less than 12 lymph nodes (LN) resected during surgery are associated with recurrence of disease [10]. Emerging advances for personalized therapy have found different molecular profiles in stage II, molecular markers as microsatellite stability (MSI) could help to decide which patients will benefit of ACh [14,15].

In our study, we retrospectively evaluated patients with stage II colon cancer, in real world data analysis with a specific emphasis on the practice of ACh selected by clinical and pathologic features.

Material and Methods
Study Design and Patients
A retrospective observational study was conducted at Oncology Section of University of Chile Clinical Hospital. Retrospectively, it was collected data from clinical record of 127 patients presented to our Oncology Committee between 2011 and 2018. These patients have clinical CRC diagnosis and histological diagnosis of T3-4N0 colon adenocarcinoma. Inclusive criteria were:

1) ≥18 years old.
2) Having been pathologically diagnosed with stage II colon cancer.
3) Having a curative intent surgery resection with lymphadenectomy
4) Having treated or controlled in our institution.

Results and Discussion
Results

| Table 1: Baseline patient characteristics. | Adjuvant chemotherapy (n=46) | Observation (n=45) |
|------------------------------------------|----------------------------|-------------------|
| Age (years)                              | 56.7 ± 12.8                | 63.4 ± 13.1       |
| Female Sex (%; n)                        | 43 (20)                    | 44 (20)           |
| Albumin (mg/dL)                          | 4.1 ± 0.3                  | 3.9 ± 0.4         |
| Hemoglobin (g/dL)                        | 12.9 ± 1.9                 | 11.8 ± 2.2        |
| Examined lymphnodes during surgery (n)   | 22 ± 10                    | 20 ± 11           |
| ≥ 1 Risk factor (%; n)                   | 89 (41)                    | 35 (15)           |
| Left colon (%; n)                        | 78 (36)                    | 67 (30)           |
| Chemotherapy regimens                    |                            |                   |
| FOLFOX (%; n)                            | 69.5 (32)                  | -                 |
| CAPOX (%; n)                             | 17.3 (8)                   | -                 |
| Capecitabine (%; n)                      | 10.9 (5)                   | -                 |

This research was presented to Ethics Committee of University of Chile Clinical Hospital.

Clinical and Pathological Data
In all patients age, sex, clinical comorbidities, surgical procedure, biopsies results, and blood samples were obtained by clinical records. Pathological examination and stage classification were according to TNM Classification of Malignant Tumours, eighth edition [16]. Also, RF were recorded, and were defined in concordance to European Society for Medical Oncology (ESMO) Clinical Practice Guidelines [17]. High risk patients were considered if they have at least one of these characteristics: lymph nodes sampling less than 12, LVI and/or PNI and pT4 stage.

Adjuvant Chemotherapy
The ACh protocols were determined by our institution Oncology Committee directed by local and international guidelines. High risk patients, according to previously mentioned criteria, were candidate to receive ACh. Chemotherapy agents include FOLFOX (leucovorin, fluorouracil and oxaliplatin), CAPOX (capecitabine and oxaliplatin), capecitabine or FU/LV (fluorouracil and leucovorin). Duration and dose were following standard doses.

Statistical Analysis
Disease-free survival (DFS) was calculated starting the first day after surgery to recurrence of tumour determined by clinical and imaging records. Due to the features of observational and real-world data study, minimum sample size was not calculated. DFS were presented in Kaplan-Meier curves and statistical differences was assessed using the log-rank test. Univariate Cox’s proportional hazards model (HR, 95% CI) was used in RF analysis. Statistical analysis and graphics were performed by GraphPad Prism 5.0 software. A significative result was considerate if p-value is less than 0.05.


Patients selection and clinical characteristics: Between 2011-2018, 127 patients initiated treatment in our institution and meeting the inclusion criteria. Sixty underwent to ACh, and 67 were observed. However, 14 patients in ACh group and 22 in observation group were excluded because they controlled and continued therapy in a different health center. Our analysis includes 46 patients in ACh group and 45 patients in observation group. Main clinical characteristics are summary in Table 1. Most patients were men (57% in ACh group, and 56% in observation group) and median age was 56.7 and 63.4 in ACh and observation group, respectively. Median follow-up was 40.3 months. ACh treatments included FOLFOX, CAPOX, capecitabine or 5FU/LV in 70, 17, 11 and 2% of patients, respectively. In ACh group a total of 93% participants concluded a 6 months treatment and only 7% terminated a 3 months scheme.

### Table 1: Regimen duration

| Regimen duration | Frequency (%, n) |
|------------------|------------------|
| 5FU/LV (%, n)    | 2.2 (1)          |
| 3 months (%, n)  | 7 (3)            |
| 6 months (%, n)  | 93 (43)          |

FOLFOX= 5-fluorouracil - oxaliplatin; CAPOX= Capecitabine – oxaliplatin; 5FU/LV: 5-fluorouracil / leucovorin

Disease-free survival: DFS in ACh group was 45 months and in observational group was 36 months, no significative difference was identified using Kaplan-Meier log-rank test (HR= 0.610 [95%CI= 0.1817 – 2.051], p = 0.277) (Figure 1). Also, no significative differences were found in clinical data as age, sex, numbers of examined lymph nodes, high risk factors, and left colon tumour location in patients with tumour recurrence in both groups. Tumour recurrence at the end of follow up was registered in a 11 (12.6%) patients (Table 2), main locations were hepatic (45.4%), local recurrence (27.2%), pulmonary (18.2%), and lymph nodes (9.1%).

![Figure 1: Disease-free survival of patient with stage II colon cancer by used of adjuvant chemotherapy and observation. No statistical significances found.](image)
Table 2: Clinical characteristics of patients with recurrence.

|                          | Adjuvant chemotherapy (n=5) | Observation (n=6) | Total (n=11) |
|--------------------------|----------------------------|------------------|-------------|
| Age (years)              | 56.6 ± 4.6                 | 66.7 ± 17.9      | 62.1 ± 14   |
| Female Sex (%), n        | 40 (2)                     | 50 (3)           | 45.4 (5)    |
| Examined lymphnodes (n)  | 28 ± 11                    | 17 ± 3           | 21.9 ± 9.3  |
| ≥ 1 Risk factor (%), n   | 80 (4)                     | 66.6 (4)         | 72.7 (8)    |
| Without Risk factor (%), n | 20 (1)                  | 33.3 (2)         | 27.3 (3)    |
| Left colon (%), n        | 80 (4)                     | 66.6 (4)         | 72.7 (8)    |
| DFS (mean months ± SD)   | 35.1 ± 27.7                | 18.0 ± 12.1      | 25.7 ± 21.5 |

Recurrence localization

|                     | Adjuvant chemotherapy (n=5) | Observation (n=6) | Total (n=11) |
|---------------------|----------------------------|------------------|-------------|
| Liver (%), n        | 40 (2)                     | 50 (3)           | 45.4 (5)    |
| Lung (%), n         | 20 (1)                     | 16.6 (1)         | 18.2 (2)    |
| Lymphnodes (%), n   | 20 (1)                     | 0                | 9.1 (1)     |
| Local recurrence (%), n | 20 (1)                  | 33.3 (2)         | 3 (27.2)    |
| Chemotherapy regimen (6 - months) |
| FOLFOX (%), n       | 80 (4)                     | -                | -           |
| Capecitabine (%), n | 20 (1)                     | -                | -           |

DFS: Disease-free survival; SD: standard deviation; FOLFOX= 5-fluorouracil - oxaliplatin;

Table 3: Univariate analysis of Disease-free survival by clinicopathological features.

|                              | p     | HR        |
|------------------------------|-------|-----------|
|                              | [95% CI]          |
| RF ≥ 1 (n=56)                | 0.757 | 0.955 [0.275 – 3.312] |
| RF = 0 (n=35)                |       |           |
| RF ≥ 1 + ACh (n= 41)         | 0.2   | 0.486 [0.092 – 2.571] |
| RF ≥ 1 + Observation (n=15)  |       |           |
| PNI-LVI (+) (n=62)           | 0.72  | 0.707 [0.215 – 2.323] |
| PNI-LVI (-) (n=29)           |       |           |
| PNI-LVI (+) + ACh (n=32)     | 0.081 | 0.271 [0.042 – 1.734] |
| PNI-LVI (+) + Observation (n=16) |       |           |

RF: Risk factors; ACh: Adjuvant Chemotherapy; PNI: Perineural infiltrate; PNI; LVI: lymphovascular infiltrate.

Risk factors: A total of 56 (62%) patients presented any RF. In this group, 41 (73%) received ACh and 15 (27%) were observed. A univariate analysis showed no statistically significant differences in DFS, independent of used therapy, in patients with T4, ILV, IPN or lymph node resected during surgery ([HR = 0.955 [95% CI = 0.275 – 3.312] p = 0.757] compared with no RF. Likewise, in high risk patients who received ACh did not indicate a significant statistical difference compared with observation. In patients with PNI and/or LVI (49%), (Table 3) ACh was associated with a tendency of higher DFS, but not statistical significant result. ([HR 0.271 [95% CI= 0.042 – 1.734], p = 0.08]. In addition, no statistical association with higher DFS was established with T4 status.

Discussion

Despite continues advances in oncology, there are still controversies about adjuvant chemotherapy in stage II colon cancer. For stage III, ACh benefits have been shown in MOSAIC study, finding a significant improvement in DFS and overall survival (OS) [9]. Consequently, a combination of oxaliplatin with fluoropyrimidine has established a standard therapy in stage III colon cancer according to European [17] and US guidelines [18]. Nevertheless, previous reports have not demonstrated the same outcomes for stage II. Results from IMPACT B2 have not evidenced a significant improvement in OS and DFS using ACh based on FU/LV compared versus surgery [19]. In contrast, QUASAR Trial documented a positive and significant benefit with FU/FV in all-cause mortality, although it is a modest improvement in absolute survival of only 3.6% at 5 years [20]. In our analysis, is not reported a statistical significant difference in DFS by adding any type of ACh compared to only observation (HR= 0.610 [95%CI= 0.1817 – 2.051], p=0.277). This reinforces the idea that ACh should not be routinely indicated in patients with stage II colon cancer. In addition, recurrence rate was 12.6%, like
other studies as Japanese Society for Cancer of the Colon and Rectum [21], that reported a 13.3% recurrence rate in a retrospective follow-up.

The principal guidelines have suggested classifying stage II according to histopathological clinical characteristics [22]. High risk profile is considered if it has any of the following characteristics: present of perineural (PNI) or lymphovascular (LVI) infiltrate in biopsy, T4 or less than 12 lymph nodes (LN) resected during surgery [10]. In fact, a worse tumour-specific survival and DFS has been reported with the presence of more than one risk factor in a patient who did not receive chemotherapy [23]. In addition, a retrospective study of stage II patients shown decrease in general mortality in patients with high risk profile who underwent to ACh compared with only surgery group. However, this same effect was not seen in DFS in same groups [24]. In our study, did not find a benefit in DFS when comparing observation and ACh groups, in high risk profile patients. Recently, it has been proposed that the addition of oxaliplatin may not be superior to fluoropyrimidine-based regimens for high-risk stage II colon cancer [25]. In our cohort, 70% of patients received FOLFOX, this amount of patients treated with oxaliplatin should be considered in interpretation of non-differences outcomes between observation and ACh in high-risk groups.

Several study limitations should be considered, due to their characteristics of retrospective and uncenter study could not be obtained a larger sample and evaluated other variables that might be a source of bias as socioeconomical status, performance status and comorbidities. The presence of microsatellite instability was not considered as a prognostic factor, since it is a measurement of recent practice in our center. Despite limitations a strength of this study is the use of real-world data methodology, that include a flexible inclusion criterion, that do not exclude older age or by comorbidities. These groups of patients have been underrepresented in randomised controlled trials [26].

Conclusion

In this retrospective and real-world data study is evidenced that usual clinical practice to select patient candidates to ACh in stage II colon cancer through high risk factor profile could be insufficient. It did not demonstrate a benefit in patients with a positive risk factor as PNI, LVI or T4. Even, a 25% of recurrences were in patients without RF. In this perspective, emerging strategies to predict a recurrences and response to ACh in stage II colon cancer are needed beyond the classical approaches of clinical and pathological risk factors.

Acknowledgements

Authors would like to thank to Surgery Department of University of Chile Clinical Hospital, as well as the administrative staff that helped with data collection and follow-up of patients.

Conflicts of Interest

The authors have no conflicts of interest to disclose.

References

1. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB, et al. (2019) Colorectal cancer. The Lancet 394(10207): 1467-80.
2. Gupta S, Bhattacharya D, Acharya AN, Majumdar S, Ranjan P, et al. (2010) Colorectal carcinoma in young adults: a retrospective study on Indian patients: 2000-2008. Colorectal carcinoma in young adults. Colorectal Dis (10 Online): e162-9.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6): 394-424.
4. Pahilman LA, Hohenberger WM, Matzel K, Sugihara K, Quirke P, et al. (2016) Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated? J Clin Oncol 34(12): 1297-1299.
5. Goovaert JA, van Dijk WA, Flocco M, Scheffer AC, Gietink L, et al. (2016) Nationwide Outcomes Measurement in Colorectal Cancer Surgery: Improving Quality and Reducing Costs. J Am Coll Surg 222(1): 19-29. e2.
6. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S, et al. (2009) Standardized surgery for colon cancer: complete mesocolic excision and central ligation - technical notes and outcome. Colorectal Dis 11(4): 354-64.
7. Böckelman C, Engelmann BE, Kaprio T, Hansen TF, Gümelius B (2015) Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature. Acta Oncol 54(1): 5-16.
8. Yothers G, O'Connell MJ, Allegro CJ, Kuebler JP, Colangelo LH, et al. (2011) Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses. J Clin Oncol 29(28): 3768-3774.
9. André T, Boni C, Navarro M, Tabernerio J, Hickish T, et al. (2009) Improved Overall Survival with Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. J Clin Oncol 27(19): 3109-3116.
10. Gill S, Meyerhardt JA, Arun M, Veenstra CM (2019) Translating IDEA to Practice and Beyond: Managing Stage II and III Colon Cancer. Am Soc Clin Oncol Educ Book (39): 226-235.
11. Dotan E, Cohen SJ (2011) Challenges in the Management of Stage II Colon Cancer. Semin Oncol 38(4): 511-520.
12. Mols F, Reijers T, Lemmens V, den Hurk CJ, Veugdenhil G, et al. (2013) Chemotherapy-Induced Neuropathy and Its Association with Quality of Life Among 2- to 11-Year Colorectal Cancer Survivors: Results from the Population-Based PROFILES Registry. J Clin Oncol 31(21): 2699-2707.
13. McClearay NJ, Benson AB, Dienstmann R (2017) Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer. Am Soc Clin Oncol Educ Book 37: 232-245.
14. Saridaki Z (2014) Prognostic and predictive significance of MSI in stages II/III colon cancer: World J Gastrenterol 20(22): 6809-6814.
15. Ishikawa T, Ishiguro M, Nakatani E, Uetake H, Ueno H, et al. (2017) Prognostic impact of MSI in stage II colon cancers: An additional translational study of the SUCRA trial. J Clin Oncol 35(15): e15155-e15155.
16. Brierley J, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours (8th Edition). John Wiley & Sons, Inc, Chichester, West Sussex, UK.
17. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, et al. (2013) Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(6): 64-72.

18. Benson AB, Venook AP, Cederquist L (2017) NCCN Clinical Practice Guidelines in Oncology: Colon Cancer.

19. (2019) International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17(5): 1356-63.

20. QUASAR Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. The Lancet 370(9604): 2020-2029.

21. Watanabe T, Itabashi M, Shimada Y, Tanaka S (2015) Japanese Society for Cancer of the Colon and Rectum, Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 20(2): 207-239.

22. Bender U, Rho YS, Barre R, Aghajanyan S, Acoba J, et al. (1999) Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions. Curr Oncol 26(1): S43-S52.

23. Gertler R, Rosenberg R, Schuster T, Friess H (2009) Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy. Eur J Cancer 45(17): 2992-2999.

24. Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, et al. (2015) Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer: Outcomes in Stage II Colon Cancer. Cancer 121(4): 527-534.

25. Chang CL, Yuan KSP, Wu ATH, Wu SY (2019) Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study. Cancers 11(12): 2003.

26. Batra A, Cheung WY (2019) Role of real-world evidence in informing cancer care: lessons from colorectal cancer. Curr Oncol 26(1): S53-S56.